摘要
目的探讨肝细胞癌患者癌组织中富含半胱氨酸肠蛋白1(CRIP1)、STIP1同源性和包含U-box蛋白1(STUB1)表达及临床预后意义。方法选取2018年2月至2020年2月该院诊治的112例肝细胞癌患者作为研究对象。免疫组化法检测肝细胞癌患者癌组织和癌旁组织中CRIP1、STUB1表达。分析肝细胞癌患者癌组织CRIP1、STUB1表达与其临床病理特征的关系。Kaplan-Meier生存分析癌组织CRIP1、STUB1表达对肝细胞癌患者预后的影响。COX回归分析影响肝细胞癌预后的因素。结果肝细胞癌患者癌组织中CRIP1阳性率为62.50%(70/112),明显高于癌旁组织[7.14%(8/112)],差异有统计学意义(χ^(2)=76.652,P<0.05)。肝细胞癌患者癌组织中STUB1阳性率为26.23%(32/112),明显低于癌旁组织[82.14%(92/112)],差异有统计学意义(χ^(2)=73.284,P<0.05)。癌组织中CRIP1与STUB1表达呈负相关(r=-0.678,P<0.001)。不同肿瘤TNM分期、组织学分级及肿瘤最大径的肝细胞癌患者癌组织中CRIP1、STUB1阳性率比较,差异有统计学意义(P<0.05)。CRIP1阳性组3年累积生存率明显低于CRIP1阴性组,差异有统计学意义(Log-rankχ^(2)=29.601,P<0.001)。STUB1阴性组3年累积生存率明显低于STUB1阳性组,差异有统计学意义(Log-rankχ^(2)=13.590,P<0.001)。肿瘤TNM分期Ⅱ~Ⅲ期、组织学分级Ⅲ级、肿瘤最大径>5 cm、CRIP1阳性、STUB1阴性是影响肝细胞癌患者预后的独立危险因素。结论肝细胞癌患者癌组织中CRIP1表达上调,STUB1表达下调,临床上可根据肝细胞癌患者癌组织中CRIP1、STUB1表达情况对患者预后进行评估。
Objective To investigate the expression of cysteine-rich intestinal protein 1(CRIP1),STIP1 homology and U-box protein 1(STUB1)in cancer tissues of patients with hepatocellular carcinoma and their clinical prognostic significance.Methods From February 2018 to February 2020,112 patients with hepatocellular carcinoma were selected as the study objects.The expression of CRIP1 and STUB1 in cancer tissues and adjacent tissues of patients with hepatocellular carcinoma was detected by immunohistochemistry.To analyze the relationship between the expression of CRIP1 and STUB1 and their clinicopathological features in hepatocellular carcinoma patients.Kaplan-Meier survival analysis of the effects of CRIP1 and STUB1 expression on the prognosis of patients with hepatocellular carcinoma.COX regression analysis was performed to analyze the prognostic factors of hepatocellular carcinoma.Results The positive rate of CRIP1 in cancer tissues of patients with hepatocellular carcinoma was 62.50%(70/112),which was significantly higher than that in adjacent tissues[7.14%(8/112)],the difference was statistically significant(χ^(2)=76.652,P<0.05).The positive rate of STUB1 in cancer tissues of patients with hepatocellular carcinoma was 26.23%(32/112),significantly lower than that in adjacent tissues[82.14%(92/112)],and the difference was statistically significant(χ^(2)=73.284,P<0.05).The expression of CRIP1 was negatively correlated with STUB1 in cancer tissues(r=-0.678,P<0.001).There were significant differences in the positive rates of CRIP1 and STUB1 in hepatocellular carcinoma patients with different TNM stages,histological grades and maximum tumor diameter(P<0.05).The 3-year cumulative survival rate of CRIP1 positive group was significantly lower than that of CRIP1 negative group,with statistical significance(Log-rankχ^(2)=29.601,P<0.001).The 3-year cumulative survival rate of STUB1 negative group was significantly lower than that of STUB1 positive group,with statistical significance(Log-rankχ^(2)=13.590,P<0.001).TNM stageⅡ-Ⅲ
作者
张景
沈晨
马鹏飞
郑幼伟
ZHANG Jing;SHEN Chen;MA Pengfei;ZHENG Youwei(Department of Hepatobiliary Surgery,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang,Henan 471000,China)
出处
《国际检验医学杂志》
CAS
2024年第3期266-271,共6页
International Journal of Laboratory Medicine
基金
河南省医学科技攻关计划项目(LHGJ20200995)。
